Conatus Pharmaceuticals Inc. (CNAT) Receives Buy Rating from Brean Capital
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating restated by equities researchers at Brean Capital in a research report issued on Tuesday.
Other equities analysts have also issued research reports about the company. Roth Capital initiated coverage on Conatus Pharmaceuticals in a research note on Friday, July 1st. They issued a “buy” rating for the company. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research note on Wednesday, August 10th. Finally, FBR & Co restated an “outperform” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Tuesday, August 30th. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $9.21.
Conatus Pharmaceuticals (NASDAQ:CNAT) traded up 6.12% during midday trading on Tuesday, reaching $2.08. The company’s stock had a trading volume of 1,492,865 shares. Conatus Pharmaceuticals has a 12-month low of $1.40 and a 12-month high of $4.62. The firm has a 50 day moving average price of $1.92 and a 200-day moving average price of $2.23. The company’s market cap is $45.91 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.08. During the same period in the previous year, the business posted ($0.31) EPS. On average, equities research analysts predict that Conatus Pharmaceuticals will post ($1.34) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. AXA raised its stake in Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock valued at $2,237,000 after buying an additional 14,939 shares during the period. Vanguard Group Inc. raised its stake in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock valued at $925,000 after buying an additional 15,300 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,668 shares during the period. Institutional investors own 22.80% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.